LOGIN

International Epidemiology Databases to Evaluate AIDS

Home >> Publications >> Comparison of genotypic and virtual phenotypic drug resistance interpretations with laboratory-based phenotypes among CRF01_AE and subtype B HIV-infected individuals.

Publication

Author(s):

Jiamsakul A1, Chaiwarith R2, Durier N3, Sirivichayakul S4, Kiertiburanakul S5, Van Den Eede P6, Ditangco R7, Kamarulzaman A8, Li PC9, Ratanasuwan W10, Sirisanthana T2; TREAT Asia Studies to Evaluate Resistance--Monitoring Study TASER-M.

Pub Title:

Comparison of genotypic and virtual phenotypic drug resistance interpretations with laboratory-based phenotypes among CRF01_AE and subtype B HIV-infected individuals.

Pub Date:

Jan 1 2016

Pub Region(s):

Asia-Pacific

Journal:

Title: 
J Med Virol

PubMed: 26147742
Pub PDF:

HIV drug resistance assessments and interpretations can be obtained from genotyping (GT), virtual phenotyping (VP) and laboratory-based phenotyping (PT). We compared resistance calls obtained from GT and VP with those from PT (GT-PT and VP-PT) among CRF01_AE and subtype B HIV-1 infected patients. GT predictions were obtained from the Stanford HIV database. VP and PT were obtained from Janssen Diagnostics BVBA's vircoType(TM) HIV-1 and Antivirogram®, respectively. With PT assumed as the "gold standard," the area under the curve (AUC) and the Bland-Altman plot were used to assess the level of agreement in resistance interpretations. A total of 80 CRF01_AE samples from Asia and 100 subtype B from Janssen Diagnostics BVBA's database were analysed. CRF01_AE showed discordances ranging from 3 to 27 samples for GT-PT and 1 to 20 samples for VP-PT. The GT-PT and VP-PT AUCs were 0.76-0.97 and 0.81-0.99, respectively. Subtype B showed 3-61 discordances for GT-PT and 2-75 discordances for VP-PT. The AUCs ranged from 0.55 to 0.95 for GT-PT and 0.55 to 0.97 for VP-PT. Didanosine had the highest proportion of discordances and/or AUC in all comparisons. The patient with the largest didanosine FC difference in each subtype harboured Q151M mutation. Overall, GT and VP predictions for CRF01_AE performed significantly better than subtype B for three NRTIs. Although discrepancies exist, GT and VP resistance interpretations in HIV-1 CRF01_AE strains were highly robust in comparison with the gold-standard PT.

The following websites provide guidelines and policies when citing from PubMed®: http://www.ncbi.nlm.nih.gov/books/NBK7243/
http://www.nlm.nih.gov/bsd/policy/cit_format.html

Citation:

J Med Virol. 2016 Feb;88(2):234-43. doi: 10.1002/jmv.24320. Epub 2015 Jul 17. Comparison of genotypic and virtual phenotypic drug resistance interpretations with laboratory-based phenotypes among CRF01_AE and subtype B HIV-infected individuals. Jiamsakul A1, Chaiwarith R2, Durier N3, Sirivichayakul S4, Kiertiburanakul S5, Van Den Eede P6, Ditangco R7, Kamarulzaman A8, Li PC9, Ratanasuwan W10, Sirisanthana T2; TREAT Asia Studies to Evaluate Resistance--Monitoring Study TASER-M.